These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 33209674)

  • 1. Gemcitabine maintenance versus observation after first-line chemotherapy in patients with metastatic urothelial carcinoma: a retrospective study.
    Kim H; Lee SH; Kim DH; Lee JY; Hong SH; Ha US; Kim IH
    Transl Androl Urol; 2020 Oct; 9(5):2113-2121. PubMed ID: 33209674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of first-line chemotherapy regimen on survival outcomes of patients with advanced urothelial carcinoma who received second-line immune checkpoint inhibitors.
    Miron B; Handorf E; Zarrabi K; Zibelman MR; Anari F; Ghatalia P; Plimack ER; Geynisman DM
    Urol Oncol; 2022 Oct; 40(10):454.e9-454.e16. PubMed ID: 35788287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial.
    Galsky MD; Arija JÁA; Bamias A; Davis ID; De Santis M; Kikuchi E; Garcia-Del-Muro X; De Giorgi U; Mencinger M; Izumi K; Panni S; Gumus M; Özgüroğlu M; Kalebasty AR; Park SH; Alekseev B; Schutz FA; Li JR; Ye D; Vogelzang NJ; Bernhard S; Tayama D; Mariathasan S; Mecke A; Thåström A; Grande E;
    Lancet; 2020 May; 395(10236):1547-1557. PubMed ID: 32416780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial.
    Scheithauer W; Ramanathan RK; Moore M; Macarulla T; Goldstein D; Hammel P; Kunzmann V; Liu H; McGovern D; Romano A; Von Hoff DD
    J Gastrointest Oncol; 2016 Jun; 7(3):469-78. PubMed ID: 27284481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maintenance monotherapy with Gemcitabine following cisplatin-based primary combination chemotherapy in surgically treated advanced urothelial carcinoma: A matched-pair single institution analysis.
    Kalogirou C; Svistunov A; Krebs M; Lausenmeyer EM; Vergho D; Riedmiller H; Kocot A
    Mol Clin Oncol; 2016 Apr; 4(4):636-642. PubMed ID: 27073682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of Maintenance Gemcitabine in Advanced Carcinoma Gallbladder.
    Sharma M; Talwar V; Maheshwari U; Koyyala VPB; Goel V; Goyal S; Dash PK; Batra U; Bajaj R; Yadav A; Goyal P; Doval DC
    South Asian J Cancer; 2020 Oct; 9(4):204-208. PubMed ID: 34131572
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy and safety of gemcitabine and capecitabine combination for patients with previously treated advanced primary pulmonary lymphoepithelioma-like carcinoma: a retrospective single-arm cohort study.
    Zou QH; Liu H; Huang CW; Kang LP; Qiu B; Mai JL; Lin YB; Liang Y
    Transl Lung Cancer Res; 2023 Jan; 12(1):96-108. PubMed ID: 36762055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemcitabine and docetaxel as second-line chemotherapy in elderly patients with metastatic urothelial carcinoma: a retrospective analysis.
    Naiki T; Iida K; Etani T; Nagai T; Tanaka Y; Sugiyama Y; Ando R; Hamamoto S; Banno R; Nagata D; Kawai N; Yasui T
    Cancer Manag Res; 2018; 10():3669-3677. PubMed ID: 30271215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.
    Powles T; van der Heijden MS; Castellano D; Galsky MD; Loriot Y; Petrylak DP; Ogawa O; Park SH; Lee JL; De Giorgi U; Bögemann M; Bamias A; Eigl BJ; Gurney H; Mukherjee SD; Fradet Y; Skoneczna I; Tsiatas M; Novikov A; Suárez C; Fay AP; Duran I; Necchi A; Wildsmith S; He P; Angra N; Gupta AK; Levin W; Bellmunt J;
    Lancet Oncol; 2020 Dec; 21(12):1574-1588. PubMed ID: 32971005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world retrospective review of monotherapy following platinum-based chemotherapy for metastatic urothelial cancer.
    Uchida H; Obinata D; Takada S; Yoshizawa T; Mochida J; Yamaguchi K; Takahashi S
    J Int Med Res; 2023 May; 51(5):3000605231173319. PubMed ID: 37226460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maintenance treatment with gemcitabine have a promising activity on metastatic bladder cancer survival.
    Kuş T; Aktaş G
    Turk J Urol; 2017 Sep; 43(3):273-278. PubMed ID: 28861297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Fever after Gemcitabine Administration is a Poor Prognostic Factor in Patients with Metastatic Urothelial Carcinoma : Multicenter Retrospective Study].
    Maehana T; Tanaka T; Shindo T; Takahashi A; Ito N; Taguchi K; Hotta H; Tachiki H; Matsukawa M; Adachi H; Kato R; Kunishima Y; Masumori N
    Hinyokika Kiyo; 2021 May; 67(5):181-185. PubMed ID: 34126660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer.
    Lim JY; Cho JH; Lee SJ; Lee DK; Yoon DS; Cho JY
    Cancer Res Treat; 2015 Apr; 47(2):266-73. PubMed ID: 25327494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-analysis of platinum chemotherapy combinations with immunotherapy in metastatic urothelial carcinoma.
    Bolek H; Yazgan SC; Yekedüz E; Ürün Y
    Oncologist; 2024 Nov; 29(11):999-1002. PubMed ID: 39340825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Effectiveness of Non-cisplatin First-line Therapies for Metastatic Urothelial Carcinoma: Phase 2 IMvigor210 Study Versus US Patients Treated in the Veterans Health Administration.
    Vander Velde N; Guerin A; Ionescu-Ittu R; Shi S; Wu EQ; Lin SW; Hsu LI; Saum KU; de Ducla S; Wang J; Li S; Thåström A; Liu S; Shi L; Leppert JT
    Eur Urol Oncol; 2019 Feb; 2(1):12-20. PubMed ID: 30929841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multi-center, Phase II trial of nab-paclitaxel and gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.
    Tachihara M; Kiriu T; Hata A; Hatakeyama Y; Nakata K; Nagano T; Yamamoto M; Kobayashi K; Ohnishi H; Katakami N; Nishimura Y
    Cancer Manag Res; 2019; 11():7135-7140. PubMed ID: 31534366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy.
    Kim SH; Lee GW; Lee MJ; Cho YJ; Jeong YY; Kim HC; Lee JD; Hwang YS; Kim IS; Lee S; Oh SY
    Lung Cancer; 2012 Sep; 77(3):578-84. PubMed ID: 22608006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma.
    Brave MH; Maguire WF; Weinstock C; Zhang H; Gao X; Li F; Yu J; Fu W; Zhao H; Pierce WF; Chang E; Dinin J; Fiero MH; Rahman NA; Tang S; Pazdur R; Kluetz PG; Amiri-Kordestani L; Suzman DL
    Clin Cancer Res; 2024 Nov; 30(21):4815-4821. PubMed ID: 39230571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial.
    Petrylak DP; de Wit R; Chi KN; Drakaki A; Sternberg CN; Nishiyama H; Castellano D; Hussain SA; Fléchon A; Bamias A; Yu EY; van der Heijden MS; Matsubara N; Alekseev B; Necchi A; Géczi L; Ou YC; Coskun HS; Su WP; Bedke J; Gakis G; Percent IJ; Lee JL; Tucci M; Semenov A; Laestadius F; Peer A; Tortora G; Safina S; Garcia Del Muro X; Rodriguez-Vida A; Cicin I; Harputluoglu H; Tagawa ST; Vaishampayan U; Aragon-Ching JB; Hamid O; Liepa AM; Wijayawardana S; Russo F; Walgren RA; Zimmermann AH; Hozak RR; Bell-McGuinn KM; Powles T;
    Lancet Oncol; 2020 Jan; 21(1):105-120. PubMed ID: 31753727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.
    Guigay J; Aupérin A; Fayette J; Saada-Bouzid E; Lafond C; Taberna M; Geoffrois L; Martin L; Capitain O; Cupissol D; Castanie H; Vansteene D; Schafhausen P; Johnson A; Even C; Sire C; Duplomb S; Evrard C; Delord JP; Laguerre B; Zanetta S; Chevassus-Clément C; Fraslin A; Louat F; Sinigaglia L; Keilholz U; Bourhis J; Mesia R; ; ;
    Lancet Oncol; 2021 Apr; 22(4):463-475. PubMed ID: 33684370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.